IL17A and neoplasm: As shown in Fig. 10, recombinant IL-17A administration could reverse the anti-tumor effect of SBE, and the volume of tumors of SBE combined with IL-17A treatment group was significantly larger than SBE treatment group (P < 0.05), and significantly smaller than vehicle control group (P < 0.05).